<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01154933</url>
  </required_header>
  <id_info>
    <org_study_id>1930</org_study_id>
    <nct_id>NCT01154933</nct_id>
  </id_info>
  <brief_title>Exeantide in Type 2 Diabetes on Insulin</brief_title>
  <official_title>The Effect of Exenatide on Insulin Requirement, Weight and Inflammation in Obese Type 2 Diabetic Subjects on Insulin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaleida Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amylin Pharmaceuticals, LLC.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kaleida Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exenatide has been shown to result in better glycemic control in type II diabetes patients.
      Obesity and diabetes are states of increased inflammation; exenatide is expected to lead to
      decreased inflammation by virtue of better glycemic control and weight loss.

      The purpose of this study is to determine if the addition of Exenatide to diabetic patients
      will reduce the requirements of insulin particularly the short acting insulin. Exenatide may
      also lead to decreased inflammation by virtue of better glycemic control and weight loss, or
      an independent effect.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>insulin dose</measure>
    <time_frame>12 weeks</time_frame>
    <description>To compare the total insulin dose at the end of 12 weeks in patients on exenatide subcutaneously twice daily (5 or 10 mcg/injection) as compared to controls in insulin treated obese type 2 diabetic patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>weight</measure>
    <time_frame>12 weeks</time_frame>
    <description>To compare the body weight at the end of 12 weeks in patients on exenatide subcutaneously twice daily (5 or 10 mcg/injection) as compared to controls in insulin treated obese type 2 diabetic patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>12 weeks</time_frame>
    <description>To compare the HbA1c at the end of 12 weeks in patients on exenatide subcutaneously twice daily (5 or 10 mcg/injection) as compared to controls in insulin treated obese type 2 diabetic patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>inflammation</measure>
    <time_frame>12 weeks</time_frame>
    <description>To investigate the hypothesis that a single dose of exenatide subcutaneously (5 mcg/injection) decreases the intranuclear NFκB binding activity and decreases the transcription of pro-inflammatory genes regulated by NFκB in MNC's of insulin treated type 2 diabetic patients as compared to placebo.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>exenatide 5 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>exenatide 5 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>exenatide 10 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>exenatide 10 mcg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exenatide 5 mcg</intervention_name>
    <description>exenatide 5 mcg</description>
    <arm_group_label>exenatide 5 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>exenatide 10 mcg</intervention_name>
    <description>exenatide 10 mcg</description>
    <arm_group_label>exenatide 10 mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>saline sq</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females 20-75 years of age inclusive.

          -  Type 2 diabetes

          -  On insulin therapy

          -  HbA1c ≥7.5% and ≤ 9%

          -  BMI ≥ 30 kg/m2

          -  Subjects on statins, ACE inhibitors, metformin, thiazolidinediones and antioxidants
             will be allowed as long as they are on stable doses of these compounds and the dosage
             in not changed during the study.

        Exclusion Criteria:

          -  Coronary event or procedure (myocardial infarction, unstable angina, coronary artery
             bypass, surgery or coronary angioplasty) in the previous four weeks

          -  Pregnancy

          -  Hepatic disease (abnormal LFT's)

          -  Use of DPP4 inhibitors.

          -  Renal impairment (serum creatinine &gt; 1.5)

          -  Participation in any other concurrent clinical trial

          -  Any other life-threatening, non-cardiac disease

          -  Uncontrolled hypertension (BP &gt; 160/100 mm of Hg)

          -  Congestive Heart Failure.

          -  Use of an investigational agent or therapeutic regimen within 30 days of study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paresh Dandona, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>SUNY at Buffalo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Millard Fillmore Gates Hospital</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2010</study_first_submitted>
  <study_first_submitted_qc>June 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2010</study_first_posted>
  <last_update_submitted>December 14, 2012</last_update_submitted>
  <last_update_submitted_qc>December 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaleida Health</investigator_affiliation>
    <investigator_full_name>Paresh Dandona, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>type 2 diabetes</keyword>
  <keyword>obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

